Celcuity Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CELC research report →
Range $140 – $178
Price Chart
About the company
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies.
- CEO
- Brian F. Sullivan
- IPO
- 2017
- Employees
- 155
- HQ
- Minneapolis, MN, US
Get TickerSpark's AI analysis on CELC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.61B
- P/E
- -11.88
- Fwd P/E
- 40.56
- PEG
- 0.50
- P/S
- 0.00
- P/B
- -41.59
- EV/EBITDA
- -15.27
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -1522.54%
- ROIC
- -35.70%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-172,192,000
- Net Income
- $-177,042,000-58.4%
- EPS
- $-3.79-33.9%
- OCF Growth
- -83.6%
- FCF Growth
- -83.4%
- 52W High
- $151.02
- 52W Low
- $53.20
- 50D MA
- $69.79
- 200D MA
- $97.40
- Beta
- 0.16
- RSI (14)
- 30
- Avg Volume
- 1.25M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Celcuity reported no third-quarter product revenue because Revtopik only launched at quarter-end, but said early launch metrics, payer coverage, and clinical momentum are encouraging.· November 5, 2026
- Revtopik was commercially available only on September 30, so Celcuity recorded no product revenue in Q3.
- Launch indicators were strong: 78% of the top 36 strategic accounts had ordered Revtopik, 3.4 thousand+ sites were engaged, and 1.1 thousand+ HCPs attended educational programs.
- Management said 91% of U.S. commercial and Medicare lives are now covered, and Revtopik was added to 3 of the 4 largest health care provider pathways within 30 days.
- Updated VIKTORIA-1 data continued to support gedatolisib in both wild-type and mutant settings, with management highlighting favorable PFS and tolerability versus alpelisib plus fulvestrant.
- Cash was $642.7 million at quarter-end, and the company said that should fund operations through 2029.
Celcuity reported third-quarter 2026 net loss of $73.3 million, or $1.33 per share, versus a net loss of $43.8 million, or $0.92 per share, a year ago. Non-GAAP adjusted net loss was $66.8 million, or $1.21 per share, versus $37.2 million, or $0.78 per share in the prior-year quarter. Total operating expenses were $77.3 million versus $42.8 million last year, with R&D at $37.5 million versus $30.4 million and SG&A at $39.8 million versus $12.4 million. The company recognized no product revenue in Q3 because shipments began on September 30 and revenue is recognized when product is delivered to the treatment location. Net cash used in operating activities was $66.2 million versus $44.8 million a year ago; a $50 million Pfizer milestone payment was also made in the quarter. Cash, cash equivalents and short-term investments were $642.7 million at quarter-end, up from $441.5 million at December 31, 2025, driven mainly by the June 2026 convertible note offering. Management said cash and investments should finance operations through 2029. Forward-looking commentary focused on a mid-January flash report for fourth-quarter sales, with no explicit quarterly revenue or EPS guidance given on the call.
Brian Sullivan framed 2026 as a transformation year as Celcuity moved into commercialization with Revtopik now available in the U.S. He emphasized that the launch is off to a strong start, pointing to rapid account uptake, broad payer coverage, and pathway inclusion as signs the company’s long investment in commercial infrastructure is working. Strategically, he said the VIKTORIA-1 data support gedatolisib across both wild-type and mutant populations and that the program could ultimately be important in breast cancer and prostate cancer. His tone was confident and upbeat, but he repeatedly noted that early launch data are still limited and mostly anecdotal.
Vicky Hahne focused on the quarter’s expense build and the balance sheet. She highlighted that SG&A rose to $39.8 million from $12.4 million, largely due to hiring and commercialization costs, while R&D increased to $37.5 million from $30.4 million. She also explained why there was no revenue in the quarter, noting that no product was received at the treatment location before September 30, and she detailed the $50 million Pfizer payment triggered by FDA approval. She closed with the company’s cash position of $642.7 million and said that liquidity should fund operations through 2029.
Analysts focused on the early Revtopik launch, asking about how much of initial prescribing came from prior trial or EAP physicians, whether the EAP was meaningful, and whether there are any inventory or supply constraints. Management said only a very small portion of prescribers came from prior studies or the EAP, described the EAP as a handful of patients, and said there is sufficient supply with the second manufacturing site not expected until mid-2027. Questions also centered on launch friction from temporary J-code status and 340B changes; Sullivan said the lack of a permanent J-code is a real but manageable obstacle, and that the new 340B rules should not affect Revtopik because Celcuity is grandfathered under the prior structure. In clinical discussion, management said doctors appear to favor the triplet over the doublet early on, while mutant-label timing and NCCN expansion depend on publication and FDA/NCCN review timelines.
The company said launch execution is strong so far, with broad account adoption, payer coverage, and pathway inclusion arriving quickly after approval. Management also emphasized favorable clinical data from VIKTORIA-1 and positive anecdotal feedback from prescribers and patients, suggesting the product is getting traction in practice. The balance sheet is also substantial, with enough cash to support operations through 2029.
Q3 had no product revenue, and near-term reported sales visibility remains limited because shipments began only at the very end of the quarter and channel data will be constrained. Management acknowledged launch friction from temporary J-code timing, institutional onboarding, and the complexity of getting some accounts fully set up, even if they do not view these as fundamental barriers. There are also ongoing regulatory and development uncertainties, including the timing of mutant-label expansion, OS maturity in VIKTORIA-1, and the second manufacturing site not expected until mid-2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 61.1%
- Shares Outstanding
- 48.93M
- Float Shares
- 29.91M
of shares held by institutions
291 13F filers
Buy/sell ratio 2.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CELC, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Baker Bros. Advisors LP | 4.82M | ▼ 3.10M |
| Rtw Investments, LP | 3.30M | 0 |
| Perceptive Advisors LLC | 3.18M | ▼ 17.41K |
| Blackrock, Inc. | 3.18M | ▲ 158.85K |
| Deerfield Management Company, L.P. | 2.40M | ▲ 946.65K |
| Vanguard Group Inc | 2.28M | ▲ 220.39K |
| State Street Corp | 2.06M | ▲ 100.87K |
| Vanguard Capital Management LLC | 1.94M | ▲ 67.35K |
| Point72 Asset Management, L.P. | 1.76M | ▲ 1.11M |
| Nea Management Company, LLC | 1.71M | 0 |
| Bank Of America Corp | 1.71M | ▲ 238.06K |
| Soleus Capital Management, L.P. | 1.68M | ▼ 21.56K |
Held by 287 ETFs
Biggest fund positions in CELC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 7, 26 | Furcht Leo | other | 250 |
| Oct 7, 26 | Furcht Leo | other | 250 |
| Oct 1, 26 | GRYSKA DAVID W | other | 893 |
| Oct 1, 26 | GRYSKA DAVID W | other | 0 |
| Aug 14, 26 | Laing Lance G. | other | 20,000 |
| Aug 14, 26 | Laing Lance G. | other | 10,000 |
| Aug 14, 26 | Sullivan Brian F. | other | 80,000 |
| Aug 14, 26 | Sullivan Brian F. | other | 120,000 |
| Aug 14, 26 | Hahne Vicky | other | 16,000 |
| Aug 14, 26 | Hahne Vicky | other | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CELC coverage
Recent articles, reports, and earnings notes.
No research on CELC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CELC report →Celcuity, Inc. $CELC Stock Sold by AlTi Global Inc.
defenseworld.net · Nov 17
Celcuity, Inc. $CELC Shares Newly Bought by ACT Capital Partners L.P.
defenseworld.net · Nov 15
Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
globenewswire.com · Nov 9
Celcuity Inc. (CELC) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 8
What Celcuity (CELC) Said on Its Q3 Earnings Call
marketbeat.com · Nov 5
Celcuity To Participate in Upcoming Investor Conferences
globenewswire.com · Nov 3
Celcuity: Stronger Clinical Evidence, Much Lower Valuation
seekingalpha.com · Oct 30
Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
globenewswire.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.